引领新科技 消除宫颈癌

HPV&宫颈癌筛查整体解决方案

HPV 16+2高危型检测——满足大规模人群筛查
HPV 21分型定量检测——优化宫颈癌精准筛查

江南体育积极响应WHO《加速消除宫颈癌全球战略》,携手共创一个没有宫颈癌的美好未来。

2020年

全球死亡病例

34.2万

2020年

全球新发病例

60.4万

如果我们不采取进一步行动,这一数据将会持续攀升。

2030年预测数据

2023年

全球死亡病例增加至

~40万

2030年

全球新发病例增加至

~70万

90%

女孩15岁前疫苗覆盖

70%

35-45岁的女性接受精准筛查

90%

宫颈病变女性接受治疗和护理

全力奔赴 加速消除宫颈癌

专利创新技术(专利号:ZL 201110087602.1)

结合HPV核酸分型定量分析软件,同步21种HPV基因分型及定量(标准化定量)

60+国家及区域

全球化营销服务网络

1000万+

江南体育HPV产品已检测超1000万人次

江南体育矢志为临床医生与适龄女性提供可靠的诊断产品与技术,积极探索「宫颈癌筛查整体解决方案」。

HPV 21分型定量检测——优化宫颈癌精准筛查

HPV 16+2高危型检测——满足大规模人群筛查

自采样检测——足不出户,轻松实现宫颈癌筛查

宫颈癌筛查精细化管理——HPV 21分型定量检测
  • A

    16

    18

    31

  • B

    59

    66

    53

  • C

    33

    58

    45

  • D

    56

    52

    35

  • E

    68

    51

    39

  • F

    82

    26

    73

  • G

    6

    11

    81

  • H

    宫颈细胞单拷贝基因

风险提示

高载量提示宫颈高级别病变风险更高,建议转诊阴道镜

感染监测

精准分型,区分HPV一过性或持续性感染

疗效观察

实时监测HPV感染者的治疗效果

术后预测

预测高级别病变术后残留的风险

专利技术(专利号:ZL 201110087602.1)

• 采用分管分型,多重荧光 PCR 定量检测

• 标准化定量:结合HPV核酸分型定量分析软件,测算同等单位细胞量内HPV载量(HPV拷贝数/10000细胞数量)

• 单次HPV检测即完成高风险人群的筛查及分流,节约成本

大规模人群筛查——HPV 16+2检测
FAM通道
16
检测HPV16型
VIC通道
18
检测HPV18型
ROX通道
26 31 33 35 39 45 51 52 53 56 58 59 66 68 73 82

检测其他HPV16种

高中危型

CY5通道
IC

检测β-globin

内参基因

  • 型别覆盖全

    一次检测,三个结果,满足初筛及分流

  • 检测通量大

    批量检测96个标本,2.5h完成一批次检测

  • 自动化检测

    荧光定量PCR平台,实现全自动检测

一站式“两癌”筛查模式

针对偏远地区、大型工业区及集中社区等场景,开发“两癌”移动筛査车,创新筛査模式,
直接将筛查车开到现场进行筛查,结合江南体育互联网医院,
可打通线上线下筛查、就诊全流程服务,实现可及化、智能化、标准化、信息化一站式闭环管理。

相关产品推荐
参考文献

1.Zhengrong Sun , Rong Zhang , Zhonghua Liu, Chao Liu, Xiulin Li, Weiqiang Zhou, Lianxia Yang, Qiang Ruan and Xu Zhang. Development of a fluorescence–based multiplex genotyping method for simultaneous determination of human papillomavirus infections and viral loads. BMC Cancer (2015) 15:860. doi 10.1186/s12885-015-1874-9 Available at: https://pubmed.ncbi.nlm.nih.gov/26546160/

2.Dong B, Sun P, Ruan G, Huang W, Mao X, Kang Y, Pan D, Lin F. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case- control study. Cancer Manag Res. 2018 Oct 23;10:4839-4851. doi: 10.2147/CMAR.S179724. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205532/

3.Chen L, Dong B, Zhang Q, Mao X, Lin W, Ruan G, Kang Y, Sun P. HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse. Med Oncol. 2020 Mar 30;37(5):37. doi: 10.1007/s12032-020-01363-z. Available at: https://link.springer.com/article/10.1007%2Fs12032-020-01363-z

4.Duan L, Du H, Wang C, Huang X, Qu X, Shi B, Liu Y, Zhang W, Duan X, Wei L, Belinson JL, Wu R. The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer. PLoS One. 2020 May 1;15(5):e0232117. doi: 10.1371/journal.pone.0232117. Available at: https://pubmed.ncbi.nlm.nih.gov/32357165/

5.Tao X, Zhang H, Wang S, Chen T, Cong Q, Wang L, Zhou X, Zhao C. Prevalence and carcinogenic risk of high-risk human papillomavirus subtypes in different cervical cytology: a study of 124,251 cases from the largest academic center in China. J Am Soc Cytopathol. 2021 Jul-Aug;10(4):391-398. doi: 10.1016/j.jasc.2021.03.006. Available at: https://www.sciencedirect.com/science/article/abs/pii/S2213294521000417

6.Li Y, Gong YX, Wang Q, Gao S, Zhang H, Xie F, Cong Q, Chen L, Zhou Q, Hong Z, Qiu L, Li F, Xie Y, Sui L. Optimizing the Detection of Occult Cervical Cancer: A Prospective Multicentre Study in China. 27 October 2021 Volume 2021:13 Pages 1005—1015. doi: 10.2147/IJWH.S329129 Available at: https://www.dovepress.com/optimizing-the-detection-of-occult-cervical-cancer-a-prospective-multi-peer-reviewed-fulltext-article-IJWH

7.Yiying Wang, Yan Wang, Michael M. Gaisa, Keith Sigel, Wenxin Zheng , Yuxin Liu , Yue Wang. Negative Predictive Value of Human Papillomavirus Testing: Implications for Anal Cancer Screening in People Living with HIV/AIDS. Journal of Oncology. 22 January 2020 Volume 2020 https://doi.org/10.1155/2020/6352315 Available at: https://www.hindawi.com/journals/jo/2020/6352315/

8.Feng?et?al. Human papillomavirus prevalence and genotype distribution landscapes in Shannan City, Tibet Tibetan Autonomous Region, China. Virology Journal (2022) 19:46 2022 Mar 18;19(1):46.?doi: 10.1186/s12985-022-01775-5 Available at: https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01775-5

9.Xiang Tao, Huina Zhang, Hao Zhang, Yaoxing Xiao, Fangfang Zhong, Xianrong Zhou, Qing Cong, Long Sui, Chengquan Zhao. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology A retrospective study of 8726 cases 2022 Mar 21.?doi: 10.1002/cncy.22573. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22573